MedTrace Logo

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

NCT05819060 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-04-19

No results posted yet for this study

Summary

The study will be a Prospective, Single-arm, Phase Ⅱ Clinical Study. This study intends to explore the efficacy and safety of Fuzuloparib combined with bevacizumab in the maintenance treatment of patients with platinum-sensitive ovarian cancer. The progression-free survival, OS, and safety were evaluated based on RECIST V1.1.

Conditions

  • Recurrent Ovarian Cancer

Interventions

DRUG

Fuzuloparib Combination with Bevacizumab

For the first 6 patients, if DLT≤33.3%, Fuzuloparib 150mg/bid will be used for follow-up research; if DLT\>33.3%, Fuzuloparib will be used for follow-up research at 100mg/bid; Bevacizumab 7.5mg/kg, d1, Q3W.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Zhong Zheng, Ph.D · Department of Gynecologic Oncology, Fudan University Shanghai Cancer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-30
Primary Completion
2024-09-30
Completion
2025-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05819060 on ClinicalTrials.gov